More importantly, in human xenografts, the JAK1/2 inhibitor Ruxolitinib exhibited potent synergism with conventional chemotherapeutic agents, including Dexamethasone, Vincristine, and Daunorubicin, thus offering an alternative therapy for this subset of Ph-like ALL. The gene discussed is JAK1; the disease is acute lymphoblastic leukemia.